- Home
- VCYT
VCYT
Veracyte Inc.
as 07-26-2024 4:00pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | N/A | IPO Year: | 2013 |
| Target Price: | $27.50 | AVG Volume (30 days): | 824.8K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.61 - $29.35 | Next Earning Date: | 08-06-2024 |
| Revenue: | $375,473,000 | Revenue Growth: | 20.66% |
| Revenue Growth (this year): | 14.58% | Revenue Growth (next year): | 10.57% |
Stock Insider Trading Activity of Veracyte Inc. (VCYT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Holstein Jens | VCYT | Director | Jul 16 '24 | Sell | $25.00 | 2,500 | $62,500.00 | 32,878 | SEC Form 4 |
| Holstein Jens | VCYT | Director | Jul 16 '24 | Sell | $24.00 | 2,500 | $60,000.00 | 35,378 | SEC Form 4 |
| EASTHAM KARIN | VCYT | Director | Jul 16 '24 | Sell | $25.00 | 7,500 | $187,500.00 | 33,228 | SEC Form 4 |
| EASTHAM KARIN | VCYT | Director | Jun 11 '24 | Sell | $20.59 | 3,870 | $79,683.30 | 29,255 | SEC Form 4 |
| Bhanji Muna | VCYT | Director | Jun 10 '24 | Sell | $20.32 | 3,870 | $78,633.76 | 23,105 | SEC Form 4 |
| EASTHAM KARIN | VCYT | Director | Jun 7 '24 | Sell | $20.97 | 2,500 | $52,425.00 | 33,125 | SEC Form 4 |
| Bhanji Muna | VCYT | Director | May 28 '24 | Sell | $21.00 | 1,539 | $32,319.00 | 26,975 | SEC Form 4 |
| EASTHAM KARIN | VCYT | Director | Apr 1 '24 | Sell | $21.65 | 10,000 | $216,528.00 | 33,125 | SEC Form 4 |
| JONES EVAN/ FA | VCYT | Director | Mar 1 '24 | Sell | $24.36 | 10,000 | $243,599.00 | 37,601 | SEC Form 4 |
Latest Veracyte Inc. News
VCYT Breaking Stock News: Dive into VCYT Ticker-Specific Updates for Smart Investing
GuruFocus.com
8 days ago
Insider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT)
Business Wire
9 days ago
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
Zacks
10 days ago
Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar?
Zacks
14 days ago
AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?
Zacks
18 days ago
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Simply Wall St.
24 days ago
Market Sentiment Around Loss-Making Veracyte, Inc. (NASDAQ:VCYT)
Zacks
a month ago
3 Medical Instruments Picks to Navigate Industry Challenges
Zacks
a month ago
Zacks.com featured highlights Veracyte, Steelcase and Applied Industrial
Compare VCYT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCYT Veracyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.